SLC5A2 and type 2 diabetes mellitus: A further study observed that, after a median follow-up time of 2.62 years, the risks of renal failure and cardiovascular events in patients with T2DM and kidney disease treated by the SGLT2 inhibitor Canagliflozin were lower than those in patients treated by a placebo [94].